Q2 FY2026 EarningsQ2 FY26 beat consensus on both top and bottom lines: total revenue was $63.3M vs. $58.9M expected, and GAAP EPS was -$0.01 vs. -$0.013 expected. Product revenue grew 10% YoY, driven by a 20% surge in INTERCEPT Fibrinogen Complex (IFC) demand. While product gross margin of 51.4% slightly missed the 52.1% consensus due to FX headwinds, management raised the lower end of full-year product revenue guidance to $229M-$231M.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Cerus(CERS) the Revenue is 57.44 M (+9.53%), Miss estimate;the EBIT is -1.858 M (+45.72%), Miss estimate;the EPS is -0.01 (+66.67%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.06B9.53%
0.06B12.31%
-0.00B2.78%
EBITMiss expectations
-0.00B45.72%
-0.00B70.66%
-0.00B24.94%
EPSExceed expectations
-0.0166.67%
-0.013355.57%
+0.003311.10%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf